BioNTech's BNT113 missed its first endpoint, analysts trimmed targets, and the Tübingen plant is set to close after deal talks collapsed. BioNTech's Oncology Transition Runs Into Clinical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results